{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:32:31Z","timestamp":1789997551561,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T00:00:00Z","timestamp":1468540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ihj.2018.01.002","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T17:46:23Z","timestamp":1515433583000},"page":"S102-S110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"S1","title":["Sacubitril\/valsartan: A novel angiotensin receptor-neprilysin inhibitor"],"prefix":"10.1016","volume":"70","author":[{"given":"Ramesh R.","family":"Dargad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh R.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit R.","family":"Dargad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai D.","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"July (3)","key":"10.1016\/j.ihj.2018.01.002_bib0005","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1016\/j.ihj.2018.01.002_bib0010","first-page":"283","article-title":"Heart failure: epidemiology and prevention in India","volume":"23","author":"Mark","year":"2010","journal-title":"Natl Med J India"},{"key":"10.1016\/j.ihj.2018.01.002_bib0015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4103\/2395-5414.182988","article-title":"Heart failure in India: the INDUS (INDia ukieri study) study","volume":"2","author":"Chaturvedi","year":"2016","journal-title":"J Pract Cardiovasc Sci"},{"issue":"22","key":"10.1016\/j.ihj.2018.01.002_bib0020","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ihj.2018.01.002_bib0025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/HYPERTENSIONAHA.115.06722","article-title":"SPRINT Study Research Group. SPRINT Trial Results: latest news in hypertension management","volume":"67","author":"Cushman","year":"2016","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.ihj.2018.01.002_bib0030","first-page":"330","article-title":"Entresto (sacubitril\/valsartan): first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure","volume":"8","author":"Fala","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.ihj.2018.01.002_bib0035","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","volume":"15","author":"McMurray","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"27","key":"10.1016\/j.ihj.2018.01.002_bib0040","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"issue":"13","key":"10.1016\/j.ihj.2018.01.002_bib0045","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/CIR.0000000000000435","volume":"134","author":"Yancy","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2018.01.002_bib0050","article-title":"ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","author":"Yancy","year":"2017","journal-title":"J Cardiac Fail"},{"key":"10.1016\/j.ihj.2018.01.002_bib0055","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/heartjnl-2014-306775","article-title":"The neprilysin pathway in heart failure: a review and guide on the use of sacubitril\/valsartan","volume":"102","author":"Jhund","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.ihj.2018.01.002_bib0060","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/phar.1629","article-title":"Neprilysin inhibition in heart failure with reduced ejection fraction: a clinical review","volume":"35","author":"King","year":"2015","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"10.1016\/j.ihj.2018.01.002_bib0065","series-title":"ENTRESTO (sacubitril and valsartan). Highlights of prescribing information","author":"U.S. Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.ihj.2018.01.002_bib0070","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/eurheartj\/ehs262","article-title":"Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics","volume":"34","author":"Mangiafico","year":"2013","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ihj.2018.01.002_bib0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1161\/CIRCHEARTFAILURE.114.001785","article-title":"Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy","volume":"8","author":"von Lueder","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ihj.2018.01.002_bib0080","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijcard.2015.03.116","article-title":"Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis","volume":"186","author":"Wang","year":"2015","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.ihj.2018.01.002_bib0085","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/1755-5922.12183","article-title":"Pharmacodynamic and pharmacokinetic profiles of sacubitril\/valsartan (LC) in patients with heart failure and reduced ejection fraction","volume":"34","author":"Kobalava","year":"2016","journal-title":"Cardiovasc Ther"},{"issue":"11","key":"10.1016\/j.ihj.2018.01.002_bib0090","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ihj.2018.01.002_bib0095","first-page":"1532","article-title":"Evaluation of pharmacokinetic and pharmacodynamic drug\u2013drug interaction of sacubitril\/valsartan (LC) and sildenafil in patients with mild-to-moderate hypertension","author":"Hsiao","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"38","key":"10.1016\/j.ihj.2018.01.002_bib0100","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","article-title":"Efficacy and safety of LC (sacubitril-valsartan) according to age: insights from PARADIGM-HF","volume":"36","author":"Jhund","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ihj.2018.01.002_bib0105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2014","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ihj.2018.01.002_bib0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jama.2015.17632","article-title":"Valsartan\/Sacubitril for heart failure: reconciling disparities between preclinical and clinical investigations","volume":"315","author":"Feldman","year":"2016","journal-title":"JAMA"},{"issue":"9851","key":"10.1016\/j.ihj.2018.01.002_bib0115","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LC in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ihj.2018.01.002_bib0120","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1161\/CIRCULATIONAHA.110.011031","article-title":"Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction","volume":"124","author":"Zile","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ihj.2018.01.002_bib0125","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jacc.2013.09.052","article-title":"Impaired systolic function by strain imaging in heart failure with preserved ejection fraction","volume":"63","author":"Kraigher-Krainer","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.ihj.2018.01.002_bib0130","first-page":"471","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction","volume":"5","author":"Solomon","year":"2017","journal-title":"JACC: Heart Fail"},{"issue":"3","key":"10.1016\/j.ihj.2018.01.002_bib0135","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.116.08556","article-title":"Effects of sacubitril\/valsartan versus olmesartan on central hemodynamics in the elderly with systolic HypertensionNovelty and significance","volume":"69","author":"Williams","year":"2017","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.ihj.2018.01.002_bib0140","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ihj.2018.01.002_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0735-1097(02)01982-4","article-title":"Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session","volume":"40","author":"Williams","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"2 pt 1","key":"10.1016\/j.ihj.2018.01.002_bib0150","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0895-7061(01)02048-9","article-title":"Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (OPERA) trial","volume":"15","author":"Kostis","year":"2002","journal-title":"Am J Hypert"},{"key":"10.1016\/j.ihj.2018.01.002_bib0155","series-title":"Presented At: American Society of Hypertension 17th Annual Scientific Session","article-title":"Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE) study: design and the results of a landmark clinical trial in hypertension","author":"Kostis","year":"2002"},{"issue":"4","key":"10.1016\/j.ihj.2018.01.002_bib0160","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2125.2003.01888.x","article-title":"Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects","volume":"56","author":"Liao","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ihj.2018.01.002_bib0165","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.112.000289","article-title":"Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure","author":"von Lueder","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ihj.2018.01.002_bib0170","first-page":"283","article-title":"Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond","volume":"11","author":"Singh","year":"2015","journal-title":"Vasc Health Risk Manage"},{"issue":"4","key":"10.1016\/j.ihj.2018.01.002_bib0175","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/HJH.0000000000001219","article-title":"Efficacy and safety of sacubitril\/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy","volume":"35","author":"Wang","year":"2017","journal-title":"J Hypert"},{"issue":"4","key":"10.1016\/j.ihj.2018.01.002_bib0180","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/hr.2015.1","article-title":"Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction","volume":"38","author":"Ito","year":"2015","journal-title":"Hypert Res"},{"issue":"1","key":"10.1016\/j.ihj.2018.01.002_bib0185","doi-asserted-by":"crossref","first-page":"e002560","DOI":"10.1161\/CIRCHEARTFAILURE.115.002560","article-title":"Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction","volume":"9","author":"Kristensen","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"5","key":"10.1016\/j.ihj.2018.01.002_bib0190","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.ihj.2018.01.002_bib0195","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/1567205012666141218140953","article-title":"Amyloid-Beta protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer\u2019s disease","volume":"12","author":"Baranello","year":"2015","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"10.1016\/j.ihj.2018.01.002_bib0200","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","article-title":"Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483216302991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483216302991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T03:57:34Z","timestamp":1570593454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019483216302991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":40,"alternative-id":["S0019483216302991"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2018.01.002","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sacubitril\/valsartan: A novel angiotensin receptor-neprilysin inhibitor","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2018.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V. on behalf of Cardiological Society of India.","name":"copyright","label":"Copyright"}]}}